Summit's ivonescimab meets PFS endpoint in global Phase III HARMONi; OS trend positive

Summit Therapeutics Inc.

Ivonescimab + chemo reduced risk of progression or death by 48% vs chemo alone (HR 0.52; p<0.00001).
Overall survival showed positive trend (HR 0.79; p=0.057), not statistically significant.
No new safety signals; Grade 3+ TEAEs 56.9% ivonescimab arm vs 50.0% control.
Summit plans to file BLA with FDA but notes FDA requires statistically significant OS benefit.
Consistent PFS benefit observed across Asia and ex-Asia (including North America) sub-populations.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.